In contrast, no effect was observed in NGAL-R− CLL cells treated either with the anti-NGAL-R or the isotype (i.e., annexin V+ cells; Figure 4B). The gene discussed is SLC22A17; the disease is B-cell chronic lymphocytic leukemia.